23 results
8-K
EX-3.1
MACA
Moringa Acquisition Corp
21 Aug 24
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
4:05pm
on behalf of the Company may pay a gratuity or pension or allowance on retirement to any Director who has held any other salaried office or place of profit
8-K
EX-10.1
MACA
Moringa Acquisition Corp
21 Aug 24
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
4:05pm
406 of the Employee Retirement Income Security Act of 1974, as amended, Section 4975 of the Internal Revenue Code of 1986, as amended, or any … of the Employee Retirement Income Security Act of 1974, if the investment decision is being made by a plan fiduciary, as defined in Section 3(21
DEFM14A
MACA
Moringa Acquisition Corp
17 Jul 24
Proxy related to merger
9:13am
by it, has agreed in the Business Combination Agreement to forfeit, for retirement, all 2,875,000 Moringa founders shares at the Closing. However, up … to 1,567,000 Moringa founders shares designated for forfeiture may, in lieu of forfeiture and retirement, be transferred by the Sponsor (upon the agreement
8-K
EX-10.2
MACA
Moringa Acquisition Corp
3 Apr 24
Entry into a Material Definitive Agreement
11:22am
surrender to TopCo for retirement (i) eight thousand (8,000) TopCo Shares, and (ii) for every $1,000 deficiency from that $500,000 amount, up … any 30-trading day period. (e) Effective as of immediately prior to the Closing, SPAC Sponsor shall surrender to the SPAC for retirement all
8-K
MACA
Moringa Acquisition Corp
3 Apr 24
Entry into a Material Definitive Agreement
11:22am
occurred since the date of the Silexion Business Combination Agreement; (iv) the forfeiture by the SPAC Sponsor for retirement of all 2,875,000 SPAC … , the SPAC Sponsor shall surrender for retirement (x) 8,000 TopCo Shares and (y) for every $1,000 deficiency from that $500,000 amount, up to a maximum
8-K
EX-2.1
s4plsfe2 71
3 Apr 24
Entry into a Material Definitive Agreement
11:22am
8-K
qtvghrxurm yef
26 Feb 24
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
5:29pm
8-K
EX-10.2
cokc a36yjb1iyf
26 Feb 24
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
5:29pm
8-K
EX-2.1
7iui8yqrt6
26 Feb 24
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
5:29pm
PRER14A
yxwpx7vkyij7e8
24 Jul 23
Preliminary revised proxy
4:45pm
PRE 14A
3oh5ujd
15 Dec 22
Preliminary proxy
5:18pm
425
EX-2.1
lz3a nsvpu
13 Jun 22
Business combination disclosure
5:15pm
425
EX-10.4.1
cdop2yrdh15
13 Jun 22
Business combination disclosure
5:15pm
8-K
EX-2.1
fre1q825l2gyo
13 Jun 22
There’s always a better travel deal out there INVESTOR PRESENTATION JUNE 2022
5:12pm